A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA study, reported as late-breaking science today at the American Heart Association’s Scientific Sessions 2023.